Answers are grounded in this paper and cite their sources.
Matched cohort study shows improved survival in high-risk myeloid malignancies after post-transplant treatment, indicating potential benefits of this approach.
Relapse is the leading cause of allogeneic hematopoietic stem cell transplant (allo-HSCT) failure in myeloid neoplasms [ 1 ]. Patients receiving reduced-intensity conditioning (RIC) regimens have a higher risk of post-transplant relapse compared to those undergoing myeloablative conditioning (MAC) [ 2 ]. However, many patients are not candidates for MAC due to age, comorbidities, or frailty. Consequently, strategies that reduce relapse risk while minimizing non-relapse mortality, such as graft-versus-host disease (GVHD), infection, and organ dysfunction, are particularly important in the RIC population [ 3 ].
No takes yet. Share an insight, caveat, or question.
Thigpen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: